Equity Overview
Price & Market Data
Price: $0.36
Daily Change: +$0.0163 / 4.53%
Range: $0.347 - $0.365
Market Cap: $82,154,880
Volume: 1,052,317
Performance Metrics
1 Week: 3.18%
1 Month: -25.17%
3 Months: -53.23%
6 Months: -54.05%
1 Year: -52.79%
YTD: -45.63%
Company Details
Employees: 115
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.